Actin plays central roles in cell motility through formation of the actin cytoskeleton. Recently, the very intriguing possibility that actin also contributes to processes in the cell nucleus has been emerging. To dissect its dynamics and functions, several actin-disrupting drugs have been widely and effectively employed. Among them, latrunculin-A has proved particularly useful, supplanting the classical drug cytochalasin-D. One reason is that latrunculin-A appears to bind only to actin monomers impairing the nucleotide exchange, the mode being simpler than with cytochalasin. This property may be especially crucial when studying actin functions as a monomer, as suggested for nuclear actin. Very importantly, actin mutations that cause cells to become resistant to the effects of latrunculin-A have been identified in budding yeast. However, it remains controversial as to whether all of the various phenotypes observed with latrunculin in mammalian cells more complicated than yeast are truly the consequence of its specific actions against actin. Here, we show that the expression of R183A D184A mutant bactin specifically confers resistance to the effects of latrunculin-A on actin cytoskeleton formation and cell growth in HeLa cells. The established system provides a strong tool to address the various functions of actin in mammalian cells. Oncogene (2003 Oncogene ( ) 22, 627-631. doi:10.1038 Actin plays central roles in cell motility processes such as cytokinesis, cell locomotion, exocytosis and endocytosis through formation of the actin cytoskeleton (Mitchson and Cramer, 1996) . Recently, the possibility that actin also functions in the cell nucleus, probably mainly in monomer form (Zhao et al., 1998; Kimura et al., 2000; Rando et al., 2000; Wasser and Chia, 2000) , has been emerging. For example, b-actin monomer has been suggested to be a functional component of the mammalian SWI/SNF-like BAF complex (Zhao et al., 1998) . It has also been suggested that nuclear b-actin bundles may be involved in the HIV Rev-dependent regulation of nucleocytoplasmic transport of viral mRNA (Kimura et al., 2000) . To dissect its dynamics and functions, several actin-disrupting drugs have been widely and effectively employed. Among them, latrunculin-A (Spector et al., 1983) , a marine toxin, has recently been preferentially applied, supplanting the classical drug cytochalasin-D. One reason for this is that latrunculin-A appears to bind only to the monomers and to impair the nucleotide exchange (Ayscough et al., 1997; Coue´et al., 1987; Morton et al., 2000) , the mode being simpler than with cytochalasin. This property may be especially crucial when assaying functions of monomeric actin, as suggested for nuclear actin. Indeed, DNA-dependent ATPase activity of the actin-monomercontaining BAF complex has been reported to be inhibited by latrunculin-B, another drug related to latrunculin-A, but not by cytochalasin-D (Zhao et al., 1998) . Importantly, actin mutations that cause cells to become resistant to the effects of latrunculin-A have been identified in budding yeast (Ayscough et al., 1997) . However, it remains controversial as to whether all of the various phenotypes observed with latrunculin treatment in mammalian cells more complicated than yeast are truly the consequence of its specific actions against actin. For example, the concentrations of latrunculin-B required for inhibiting the DNA-dependent ATPase activity of the BAF complex or the specific nucleocytoplasmic transport of HIV mRNA appear very high, as compared with that disrupting cytoplasmic actin filaments (Zhao et al., 1998; Kimura et al., 2000) . Also, it has yet to be clarified why receptor-mediated endocytosis or neurotransmitter release, both of which are suggested to be regulated by actin, are affected by latrunculin-A but not by cytochalasin-D (Lamaze et al., 1997; Morales et al., 2000) . Establishment of latrunculin-resistant mutant actin in a mammalian cell system should allow these questions to be answered.
In budding yeast, three latrunculin-A-resistant mutant actins have been identified (Wertman et al., 1992; Ayscough et al., 1997) . Among them, R183A D184A mutant actin is of special interest, since its expression is not associated with cytotoxicity (Ayscough et al., 1997) . Furthermore, it has also been shown that purified R183A D184A mutant actin is resistant to the action of latrunculin-A in vitro (Ayscough et al., 1997) . Although the amino-acid sequence of actin is very well conserved among eukaryotes, the affinity of many actinbinding proteins from mammals for yeast actin is weak, suggesting that yeast actin could not function well in mammalian cells. Nevertheless, since Arg 183 and Asp 184 are conserved in mammalian actin, we hypothesized that R183A D184 mutant mammalian actin should also be resistant to latrunculin-A. If this were the case, establishing mammalian cells expressing such mutant actin undoubtedly would facilitate studies of actin using latrunculin. We therefore sought to establish HeLa cells overexpressing R183A D184A mutant b-actin. The reasons why we chose b-actin are that (i) it is the major nonmuscle actin and (ii) it has been suggested to function in nuclei.
For expression of the R183A D184A mutant b-actin, we chose a tetracycline-regulated expression system for the following reasons. (i) Its expression is driven by the strong hybrid transactivator tTA so that high levels are achievable. (ii) It is possible to confirm whether the phenotypes of established cells indeed result from the overexpressed mutant b-actin by regulating the expression. The vector pOTb-actinRADA expressing the mutant b-actin under the control of tTA responsive promoter was cotransfected with hygromycin-resistance gene into HeLa Tet-off cells expressing tTA. As a control, pOTb-actin encoding wild-type b-actin was also transfected. We first selected the transfected cells with 200 mg/ml hygromycin-B, and obtained about 160 hygromycin-resistant colonies/2 Â 10 6 starting cells both with pOTb-actin and pOTb-actinRADA. We next added 1 mg/ml latrunculin-A to the colonies, continued the culture for about 2 weeks without further addition of the drug, and obtained about 30 colonies that survived with pOTb-actinRADA, but none with pOTb-actin. Several colonies were picked up, expanded to confluence, and then selected with 2 mg/ml latrunculin-A. Most cells thereby died, but the remainder were then expanded without latrunculin-A. Such selection was further repeated with 4 mg/ml latrunculin-A, and finally two lines, termed RADA2-1-4 and RADA4-1-4, were established. As controls, we used a mixture of HeLa Tetoff cells transfected with pOTb-actin and selected only with hygromycin-B, termed beta-mix. To prepare RADA2-1-4 and RADA4-1-4 cells in which expression of the mutant actin is repressed, they were maintained in the presence of 1 mg/ml doxycycline for 10 days and then subjected to assays.
Using two-dimensional gel electrophoresis followed by Coomassie blue staining, we examined the expression of the mutant b-actin. As reported previously (Toyama and Toyama, 1984) , b-actin was detected as a discrete major spot, with an apparent molecular weight of about 47 kDa and an isoelectric point of about 5.2, g-actin being detected with a somewhat more basic isoelectric point ( Figure 1A) . These values are in agreement with the expected ones, and the two spots reacted well with anti-actin antibody (data not shown). To determine signal intensities, the stained gels were scanned. Setting the level for the g-actin spot at 100, the relative level of the b-actin spot in control beta-mix cells was about 270 ( Figure 1A(a) ). In RADA2-1-4 cells, the relative level for the b-actin spot was about 1500, and when the cells were treated with doxycycline, it decreased to 170 ( Figure 1A(b) and (c) ). These data clearly indicate that RADA2-1-4 cells express the R183A D184A mutant bactin in levels 6-7 times as high as endogenous b-actin and that the expression is suppressed by doxycycline treatment, although we could not separate mutant bactin from endogenous b-actin with two-dimensional gel electrophoresis. Similarly, it is also indicated that RADA4-1-4 cells express the mutant b-actin at twice the level of endogenous b-actin, again suppressed by doxycycline treatment (Figure 1A(d) and (e) ).
To further confirm the expression of the mutant bactin, we performed the reverse transcriptase-polymerase chain reaction (RT-PCR) with a primer set designed to amplify both endogenous and exogenous b-actin mRNAs. Although the sizes for RT-PCR products derived from endogenous, exogenous and the mutant bactin are the same (1076 bp), they could be discriminated by restriction enzyme digestion ( Figure 1C ). The cDNA used for expression of exogenous b-actin protein is a chimera of b-actin and g-actin cDNAs (Ohmori et al., 1992) , and thus the RT-PCR products have a unique Acc III site. Furthermore, the RT-PCR products derived from the mutant b-actin mRNA have a new NarI site (GGCGCC) in addition to two common NarI sites (see also the legend for Figure 1A ). Since our PCR analysis was not quantitative, we could not estimate the amount of b-actin mRNA in each cell line. However, levels of the mutant b-actin mRNA relative to the endogenous form could be assessed by comparing the signal intensity of the NarI-digested products with that of the remnant products. Total RNAs were isolated from control beta-mix cells, RADA2-1-4 cells and RADA2-1-4 cells treated with doxycycline, and subjected to RT-PCR, the products being electrophoresed and visualized with ethidium bromide staining. In all the samples, a clear band of 1076 bp was observed ( Figure 1B) . No product was obtained without RNA or the RT reaction (data not shown). When the PCR products were digested with NarI and analysed, an 830 bp form and a mixture of 108 and 115 bp products were obtained in the sample from beta-mix cells, as expected ( Figure 1B) . In contrast, additional products, a mixture of 441 and 411 bp products, were observed in RADA2-1-4 cells, clearly demonstrating expression of the mutant b-actin mRNA ( Figure 1B) . It was also clear that the expression was suppressed by doxycycline treatment ( Figure 1B) . By quantifying the digested and remnant products, the level of the mutant b-actin mRNA in RADA2-1-4 cells was estimated to be 2-3 times higher than that of endogenous b-actin. This estimation is somewhat lower than that with two-dimensional gel electrophoresis. The exact reason for the difference is unclear at present. The forward primer was designed to be specific for b-actin, featuring a 20% mismatch with a g-actin sequence. Indeed, Acc III digestion of the RT-PCR products from doxycycline-treated RADA2-1-4 cells yielded no digested products (data not shown), Figure 1 Overexpression of the R183A D184A mutant b-actin in RADA2-1-4 and RADA4-1-4 cells and its suppression by doxycycline. The Tet system vector pOTb-actin expressing b-actin protein under the control of a tTA responsive promoter was kindly provided by Dr Toyama. The cDNA is a chimera of b-actin and g-actin cDNAs, but in fact encodes wild-type b-actin protein (Ohmori et al., 1992) . To generate pOTb-actinRADA expressing the R183A D184A mutant b-actin, oligonucleotide-directed mutagenesis (QuikChange Site-directed Mutagenesis Kit; Stratagene) was performed with an oligonucleotide 5 0 -GCGTCTGGACC TGGCTGGCGCCGCCCTGACCGACTACC-3 0 and its complementary oligonucleotide. The underlined sequence encodes mutated Ala 183 and Ala 184. The sequence of the resultant cDNA was confirmed by sequencing. Plasmids (3.6 mg) were cotransfected with pTKhyg (0.4 mg) into 2 Â 10 6 HeLa Tet-off cells expressing tTA (Clontech) with LIPOFECTIN and PLUS reagents (GIBCO BRL). RADA2-1-4 and RADA4-1-4 cells expressing the mutant b-actin, and beta-mix cells as a control, were established as described in the text. (A) Analysis of mutant b-actin expression by two-dimensional gel electrophoresis. Approximately 1 Â 10 7 cells were lysed in 1 ml lysis buffer (7 m urea, 2 m thiourea, 2% Triton X-100, 0.1 m dithiothreitol, 1% pharmalyte) containing multiple protease inhibitors, and 10 ml aliquots of lysate were subjected to isoelectric focusing with immobiline gels (18 cm long, pH 4.5-5.5; Pharmacia). After second dimensional SDS-PAGE, the proteins were stained with Coomassie blue, and scanned for the determination of signal intensities of single spots with Pharmacia Image Master. The part of each gel relevant to actin proteins is shown. The signal intensities of the b-actin spots were determined, relative to the g-actin spot set at 100. Dox, doxycycline. (B) Analysis of mutant b-actin mRNA expression by RT-PCR. Total RNAs were extracted using an RNeasy kit (QIAGEN), and 0.5 mg aliquots were subjected to one-step RT-PCR with a QIAGEN OneStep RT-PCR kit. The primer set used for one-step RT-PCR of b-actin mRNA comprised the forward primer 5 0 -ATGGATGATGATATCGCCGCGCTCGTCGTC-3 0 and the reverse primer 5 0 -CTGATCCACATCTGCTGGAAGGTGGA-CAGC-3 0 . Conditions for one-step RT-PCR were as follows: RT reaction at 501C for 30 min; hot start activation of Taq polymerase at 951C for 15 min; 30 PCR cycle at 941C for 30 s, 651C for 60 s and 721C for 90 s. The RT-PCR products were purified, electrophoresed in 2% agarose gels directly or after NarI digestion, and visualized with ethidium bromide staining. Signal intensities of the stained products were determined with LumiVisionPRO (AISIN, Japan). (C) Schematic representation of the RT-PCR products from actin mRNAs obtained with the primers described above. For details, see the text Latrunculin-resistant HeLa cells by a mutant actin M Fujita et al confirming that g-actin mRNA is not amplified under our experimental conditions. Analysis of the RT-PCR products after Acc III digestion also showed the relative expression level of exogenous b-actin in beta-mix cells to be very low compared with its endogenous counterpart (data not shown). Overall, the results obtained with the RT-PCR assay are well compatible with those from two-dimensional gel electrophoresis.
We next examined the sensitivity of the cells to growth inhibitory effects of latrunculin-A and cytochalasin-D (Figure 2 ). RADA2-1-4 cells were about 6-7 times, and RADA4-1-4 cells were about 4 times more resistant to latrunculin-A than the control beta-mix cells, in line with their levels of expression of R183A D184A mutant b-actin (Figure 1) . When the expression of the mutant bactin was suppressed by doxycycline, their levels of sensitivity to latrunculin-A reverted to that of the control cells. Note that doxycycline itself had no effect on growth inhibition by latrunculin-A in control betamix cells. It is also notable that the sensitivity of RADA2-1-4 and RADA4-1-4 cells to cytochalasin-D was unchanged compared with the control cells, either in the presence or the absence of mutant actin. We also investigated the sensitivity of the cells to disruption of actin filament bundles by the drugs. In control beta-mix cells, actin filaments detected by phalloidin staining began to break down either with latrunculin-A or cytochalasin-D at a concentration of 0.1 mg/ml (data not shown), and became undetectable at 0.25 mg/ml (Figure 3b and d) . In contrast, in most RADA2-1-4 and RADA4-1-4 cells treated with 0.25 mg/ ml latrunculin-A, actin filaments were detectable (Figure 3f and j) , and even with 0.5 mg/ml latrunculin-A, cells with intact actin fibers still remained (Figure 3g and k) although the number with disrupted actin fibers was increased. Such resistance of RADA2-1-4 and RADA4-1-4 cells was lost when the expression of the R183A D184A mutant b-actin was suppressed by doxycycline (Figure 3n and r) . Again, it is notable that the sensitivity to disruptive effects of cytochalasin-D on actin filaments was virtually unchanged compared with the control cells (Figure 3d , h and l).
Taken together, these data clearly show that the R183A D184A mutant b-actin specifically confers resistance against inhibitory effects of latrunculin-A on actin cytoskeleton formation and cell growth in HeLa cells, and thus these effects are indeed because of the action of latrunculin-A against actin. The possibility that the resistance was simply attributable to abundant exogenous actin rather than to the specific mutation was precluded by the following. (i) We could not obtain latrunculin-A-resistant cells by transfection of a vector encoding wild-type b-actin. (ii) The established cells are specifically resistant to latrunculin-A and not cytochalasin-D. On the other hand, the extent of the resistance of the established HeLa cells to latrunculin-A appears somewhat less than that demonstrated by yeast cells expressing the mutant actin (Ayscough et al., 1997) , suggesting the possibility that the drug might also act on molecule(s) other than actin in mammalian cells. Whatever, with the established HeLa cells and mutant actin expression system, we can now examine precisely whether phenotypes observed with latrunculin-A treatment in mammalian cells in fact result from its actions against actin. In our system, the expression of the mutant actin is controllable by doxycycline, more advantageous to such purpose. Further studies with this approach should help generate a deeper understanding of newly emerging, that is nuclear, as well as classical functions of actin in mammalian cells.
